3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer
Cur rently, the search for additional organ-sparing methods of intravesical therapy for non-muscular-invasive bladder cancer (NMIBC) is actively continuing, which could become an effective alternative to standard treatment using the Bacillus Calmette-Guérin (BCG) vaccine. The aim of this work was...
Saved in:
Main Authors: | R.S. Chystiakov, F.I. Kostyev, O.V. Bondar, V.V. Lysenko, V.O. Varbanets |
---|---|
Format: | Article |
Language: | English |
Published: |
Dnipro State Medical University
2023-06-01
|
Series: | Medičnì Perspektivi |
Subjects: | |
Online Access: | https://journals.uran.ua/index.php/2307-0404/article/view/283254 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC)
by: Laila Schneidewind, et al.
Published: (2025-02-01) -
Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024-11-01) -
Analgesic effect of intravesical lignocaine in urology surgery: A systematic review and meta-analysis
by: Ka T. Ng, et al. -
Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain
by: Hideyuki Isobe, et al.
Published: (2025-01-01) -
Efficacy analysis of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer: a retrospective study
by: Zhijie Gong, et al.
Published: (2025-01-01)